Guangzhou Innogen Pharmaceutical Group Co Ltd Class H 2591

Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today announced that its Efsubaglutide alfa manufacturing facility in Suzhou has officially passed a compliance inspection conducted by the Brazilian National Health Surveillance Agency (ANVISA) in accordance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practice (GMP) standards, and has received the GMP certificate